Does TYK2/JAK1 Show Potential in Inflammatory Diseases? - Scorecard - MDSpire

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

  • By

  • Andrea Surnit

  • July 6, 2026

  • 3 min

Share

Clinical Scorecard: Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

At a Glance

CategoryDetail
ConditionInflammatory Diseases
Key MechanismsInhibition of TYK2 and JAK1 pathways
Target PopulationHealthy participants
Care SettingPhase 1 clinical trial

Key Highlights

  • SDC-1801 was well tolerated with mild to moderate adverse events.
  • Evidence of pharmacologic activity with reductions in IP-10 and high-sensitivity C-reactive protein.
  • Peak plasma concentrations observed 3 to 5 hours post-administration.
  • Food intake modestly increased drug exposure.
  • Limited renal elimination with less than 4% recovered unchanged in urine.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

        • One participant experienced treatment-related rhabdomyolysis.

        Patient & Prescribing Data

        Healthy participants in a clinical trial

        Potential for once- or twice-daily dosing based on pharmacokinetic data.

        Clinical Best Practices

        • Monitor for mild to moderate adverse events during treatment.
        • Consider food effects on drug absorption when prescribing.

        Related Resources & Content

        Original Source(s)

        Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

        • by Andrea Surnit

        • July 6, 2026

        Related Content

        Musculoskeletal ultrasound discriminating camptodactyly-arthropathy-coxa vara-pericarditis syndrome and juvenile idiopathic arthritis

        First HIV-Positive-to-HIV-Positive Lung Transplant Reported

        The procedure was performed under a HOPE Act research protocol at an NYU Langone Health center the institution said is among the limited number of US transplant centers equipped and approved to perform HOPE lung transplants.

        Systemic lupus erythematosus–driven accelerated atherosclerosis: the immune–metabolic–vascular axis and therapeutic implications